POM-V Prescription Required

Bovalto Respi Intranasal, Nasal Spray, Lyophilisate and Solvent for Suspension

Active ingredients: Bovine parainfluenza virus 3, Bovine respiratory syncytial virus

Form

Spray

Species

Cattle

Manufacturer

Boehringer Ingelheim Animal Health UK Limited

VMD MA No.

08327/5006

What it's used for

For the active immunisation of calves from the age of 10 days against bovine respiratory syncytial virus (BRSV) and bovine parainfluenza virus (BPIV-3), to...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Bovine parainfluenza virus 3...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bovalto Respi Intranasal, Nasal Spray, Lyophilisate and Solvent for Suspension — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For the active immunisation of calves from the age of 10 days against bovine respiratory
syncytial virus (BRSV) and bovine parainfluenza virus (BPIV-3), to reduce the quantity and
duration of nasal excretion of both viruses.
Onset of immunity: 10 days after vaccination
Duration of immunity: 12 weeks after vaccination.

Revised: May 2025
AN: 02835/2024Page 2 of 5

None.

Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Hypersensitivity reaction*
*may require appropriate symptomatic treatment
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary
medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing
authorisation holder or the national competent authority via the national reporting system. See
also the last section of the package leaflet for respective contact details.

The laboratory efficacy studies have demonstrated that the presence of maternally derived
antibodies at the time of vaccination had no impact on vaccine efficacy in young animals.
Vaccinate healthy animals only.

Special precautions for use in animals:
Vaccinated calves can excrete the vaccine strains BRSV and BPIV-3 for up to 6 days after
vaccination. Therefore, the spread of the vaccine virus from vaccinated to unvaccinated
calves cannot be excluded. Animals should be vaccinated at least 10 days before the critical
period of stress or high risk of infection, such as rearrangement or transport of animals, or in
early autumn. To achieve optimal results, it is recommended to vaccinate all calves of the
herd.
Special precautions to be taken by the person administering the veterinary medicinal product
to animals:
Not applicable.
Special precautions for the protection of the environment:
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with any
other veterinary medicinal products. A decision to use this vaccine before or after any other
veterinary medicinal product therefore needs to be made on a case by case basis.

Lyophilisate and solvent:
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from direct sunlight.
Reconstituted vaccine:
Store below 25°C. Do not freeze.

– 10
7.5
TCID
Bovine respiratory syncytial virus, strain Bio 24/A, live 10
4.0
– 10

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.